ATAI Life Sciences Archives

Psychedelics News

ATAI Life Sciences

Industry

6 Jul 2022

ATAI Files For Potential $300M Capital Raise

Atai has filed a shelf prospectus for up tp $300 million in new capital...

By Jason Najum

Finance

8 Apr 2022

Christian Angermayer Buys 1 Million Shares of ATAI

Psychedelic medicine is a long-term play and atai founder Christian Angermayer has just given us a multi-million dollar reminder...

By Jason Najum

Finance

30 Mar 2022

ATAI Announces Fourth Quarter and Full Year 2021 Results

With the sector in the midst of a (very) extended pullback, these results provide opportunities to re-focus our attention on the details of the company’s progress and away from the...

By Jason Najum

Finance

7 Mar 2022

Cathie Wood Continues to Buy More ATAI Stock

ARK is doubling down on its psychedelic bet, showing that it believes in the innovative potential of the sector....

By Jason Najum

Join Our Newsletter for Exclusive Updates, Stories, and More

Breaking News

10 Feb 2022

Star Investor Cathie Wood Finally Buys Into Psychedelics

ARK Genomic Revolution ETF bought 83,278 shares of atai Life Sciences, its first foray into psychedelics....

By Jason Najum

Industry

27 Jan 2022

ATAI Launches Discovery Program for Next-Gen Mental Health Treatments

This new platform company is a further step-up in atai’s commitment to next-generation treatment...

By Microdose

Finance

14 Jan 2022

Psychedelic Stocks to Watch in 2022

While 2022 hasn’t yet given us the market turnaround we had hoped for, the forthcoming 12 months will filled with clinical trial news and significant milestones....

By Jason Najum

Industry

29 Nov 2021

ATAI Increases Ownership in COMPASS Pathways

Atai Life Sciences, the psychedelic medicine industry’s leader by market cap, has announced the purchase of another 619,095 Compass Pathways shares....

By Jason Najum

Finance

20 Oct 2021

H.C. Wainwright Gives atai Life Sciences a Buy Rating and $40 Price Target

H....

By Jason Najum

Follow us on social

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

Professional Training in Psychedelic Medicine

Psychedelic medicine is reshaping the future of mental health care. From the power of microdosing LSD to the promise of MDMA in PTSD, the world of medical psychedelics offers transformative possibilities. Our comprehensive, CE-accredited course provides you with the knowledge and understanding you need to tap into this groundbreaking field.

WordPress Ads

No Result

View All Result